Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Long-Term Deferred Tax (2020 - 2025)

Neurocrine Biosciences' Long-Term Deferred Tax history spans 7 years, with the latest figure at $320.3 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 34.05% year-over-year to $320.3 million; the TTM value through Dec 2025 reached $320.3 million, down 34.05%, while the annual FY2025 figure was $320.3 million, 34.05% down from the prior year.
  • Long-Term Deferred Tax reached $320.3 million in Q4 2025 per NBIX's latest filing, down from $368.5 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $536.8 million in Q2 2025 to a low of $305.9 million in Q4 2022.
  • Average Long-Term Deferred Tax over 5 years is $373.6 million, with a median of $350.0 million recorded in 2023.
  • Peak YoY movement for Long-Term Deferred Tax: surged 33.95% in 2024, then tumbled 34.05% in 2025.
  • A 5-year view of Long-Term Deferred Tax shows it stood at $315.1 million in 2021, then decreased by 2.92% to $305.9 million in 2022, then grew by 18.54% to $362.6 million in 2023, then soared by 33.95% to $485.7 million in 2024, then crashed by 34.05% to $320.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Long-Term Deferred Tax are $320.3 million (Q4 2025), $368.5 million (Q3 2025), and $536.8 million (Q2 2025).